These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29563772)

  • 21. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
    Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
    Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
    Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y
    World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
    Young R; Mainwaring P; Clingan P; Parnis FX; Asghari G; Beale P; Aly A; Botteman M; Romano A; Ferrara S; Margunato-Debay S; Harris M
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e325-e331. PubMed ID: 29932294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Li W; Wang H; Li X
    Curr Med Res Opin; 2013 Nov; 29(11):1443-52. PubMed ID: 23927481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
    Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
    N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
    Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
    Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
    Xiao BY; Wang BC; Lin GH; Li PC
    Ann Palliat Med; 2020 Jul; 9(4):1631-1642. PubMed ID: 32576005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
    Lu S; Zhang Y; Zhou X; Zhou D; Yang Q; Ju B; Zhao X; Hu Z; Xie H; Zhou L; Zheng S; Wang W
    Sci Rep; 2016 Nov; 6():36944. PubMed ID: 27833144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 31. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
    Cascinu S; Berardi R; Bianco R; Bilancia D; Zaniboni A; Ferrari D; Mosconi S; Spallanzani A; Cavanna L; Leo S; Negri F; Beretta GD; Sobrero A; Banzi M; Morabito A; Bittoni A; Marciano R; Ferrara D; Noventa S; Piccirillo MC; Labianca R; Mosconi C; Casadei Gardini A; Gallo C; Perrone F
    Eur J Cancer; 2021 May; 148():422-429. PubMed ID: 33812334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
    Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
    Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
    Sultana A; Smith CT; Cunningham D; Starling N; Neoptolemos JP; Ghaneh P
    J Clin Oncol; 2007 Jun; 25(18):2607-15. PubMed ID: 17577041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Int J Clin Oncol; 2013 Dec; 18(6):1005-13. PubMed ID: 23212559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
    Dig Liver Dis; 2014 May; 46(5):452-9. PubMed ID: 24565950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
    Ishimoto U; Kinoshita A; Hirose Y; Shibata K; Ishii A; Shoji R; Yokota T; Iwaku A; Mizuno Y; Koike K; Saruta M
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):647-654. PubMed ID: 31230157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
    Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
    Hu ZI; Bendell JC; Bullock A; LoConte NK; Hatoum H; Ritch P; Hool H; Leach JW; Sanchez J; Sohal DPS; Strickler J; Patel R; Wang-Gillam A; Firdaus I; Yu KH; Kapoun AM; Holmgren E; Zhou L; Dupont J; Picozzi V; Sahai V; O'Reilly EM
    Cancer Med; 2019 Sep; 8(11):5148-5157. PubMed ID: 31347292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.